- Home
- MRVI vs BCAR Comparison
MRVI vs BCAR Comparison
Compare MRVI & BCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- BCAR
- Stock Information
- Founded
- MRVI 2014
- BCAR 2025
- Country
- MRVI United States
- BCAR United States
- Employees
- MRVI N/A
- BCAR N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- BCAR Blank Checks
- Sector
- MRVI Health Care
- BCAR Finance
- Exchange
- MRVI Nasdaq
- BCAR Nasdaq
- Market Cap
- MRVI 376.2M
- BCAR 419.8M
- IPO Year
- MRVI 2020
- BCAR 2025
- Fundamental
- Price
- MRVI $3.14
- BCAR $10.05
- Analyst Decision
- MRVI Hold
- BCAR
- Analyst Count
- MRVI 9
- BCAR 0
- Target Price
- MRVI $4.54
- BCAR N/A
- AVG Volume (30 Days)
- MRVI 1.7M
- BCAR 124.6K
- Earning Date
- MRVI 11-06-2025
- BCAR 01-01-0001
- Dividend Yield
- MRVI N/A
- BCAR N/A
- EPS Growth
- MRVI N/A
- BCAR N/A
- EPS
- MRVI N/A
- BCAR N/A
- Revenue
- MRVI $219,830,000.00
- BCAR N/A
- Revenue This Year
- MRVI N/A
- BCAR N/A
- Revenue Next Year
- MRVI $7.27
- BCAR N/A
- P/E Ratio
- MRVI N/A
- BCAR N/A
- Revenue Growth
- MRVI N/A
- BCAR N/A
- 52 Week Low
- MRVI $1.67
- BCAR $9.88
- 52 Week High
- MRVI $8.29
- BCAR $10.06
- Technical
- Relative Strength Index (RSI)
- MRVI 48.93
- BCAR N/A
- Support Level
- MRVI $3.01
- BCAR N/A
- Resistance Level
- MRVI $3.55
- BCAR N/A
- Average True Range (ATR)
- MRVI 0.19
- BCAR 0.00
- MACD
- MRVI -0.06
- BCAR 0.00
- Stochastic Oscillator
- MRVI 20.31
- BCAR 0.00
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About BCAR D. Boral ARC Acquisition I Corp. Class A Ordinary Shares
D Boral ARC Acquisition I Corp is a blank check company.